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Phenylketonuria (PKU) is an inherited metabolic disease characterized by abnormally
high concentrations of the essential amino acid L-phenylalanine (Phe) in blood plasma
caused by reduced activity of phenylalanine hydroxylase (PAH). While numerous studies
have shown association between high plasma Phe concentration and intellectual
impairment, it is not clear whether increased Phe fluctuations also observed in PKU
affect the brain as well. To investigate this, time-resolved in vivo data on Phe and
competing large neutral amino acid (LNAA) concentrations in neurons are needed, but
cannot be acquired readily with current methods. We have used in silico modeling as an
alternative approach to characterize the interactive dynamics of Phe and competing
LNAAs (CL) in the neurovascular unit (NVU). Our results suggest that plasma Phe
fluctuations can propagate into the NVU cells and change there the concentration
of LNAAs, with the highest magnitude of this effect observed at low frequency and
high amplitude-to-mean ratio of the plasma Phe concentration fluctuations. Our model
further elucidates the effect of therapeutic LNAA supplementation in PKU, showing
how abnormal concentrations of Phe and CL in the NVU move thereby toward normal
physiologic levels.
Keywords: phenylketonuria, L-phenylalanine fluctuation, neurovascular unit, amino acid transporter, large neutral
amino acid
INTRODUCTION
Phenylketonuria (PKU) is the most common disorder of amino acid (AA) metabolism, resulting
from severely reduced activity of the liver enzyme phenylalanine hydroxylase (PAH), which
leads to abnormal accumulation of the essential amino acid L-phenylalanine (Phe) in the blood
plasma (Güttler et al., 1969; Madden, 2004; Regier and Greene, 2017). Phe is transported across
the blood brain barrier (BBB) into the neurovascular unit (NVU), where abnormal increase
in its concentration leads to imbalance of large neutral amino acid (LNAA) levels in brain
interstitial fluid (ISF), astrocytes and neurons, as a consequence of the competition for NVU-LNAA
transporters (van Spronsen et al., 2010). Since NVU-LNAAs are required for the synthesis of
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essential neurotransmitters such as dopamine, serotonin, and
norepinephrine, their perturbations can lead to intellectual
disabilities, growth abnormalities and severe behavioral problems
in PKU patients (Güttler et al., 1969; Cleary et al., 2013).
The dysfunction of the PAH enzyme is also the cause of higher
than normal fluctuations in Phe plasma concentration, where
patterns greatly vary among patients in relation to age, diet,
genotype and level of PAH defect (Burgard et al., 1996; Cleary
et al., 2013). Nevertheless, only time-averaged Phe concentrations
are used to classify PKU severity (benign, mild or classic) and
design the treatment protocol, which consists mainly of a low
Phe diet to reduce mean blood Phe concentration (Cleary et al.,
2013; Belanger et al., 2018). However, the effectiveness of such
therapies depends on the concentrations of LNAAs in the NVU,
which can influence brain function and behavior, rather than
directly the blood Phe level (Cleary et al., 2013). Some studies
have specifically investigated the relation between brain function
(assessed through intelligence quotient (IQ) tests) and mean
plasma Phe concentration and its fluctuations. The results were
not conclusive: while in some studies IQ was found to be more
often associated with the level of Phe fluctuations in the plasma
rather than with its mean value (Hood et al., 2014; Romani et al.,
2017), the opposite was reported in others (Viau et al., 2011; Hood
et al., 2015), while no differentiation was possible in yet another
one (Burgard et al., 1996). The reasons for this inconsistency are
not clear, but could be, in part, a reflection of how fluctuations
in plasma Phe concentration translate in individual patients to
effects on AA homeostasis in the brain (Cleary et al., 2013).
The propagation of Phe fluctuations from plasma into
the brain is critically influenced by the competition between
this AA and its competing LNAAs (CL, i.e., L-leucine,
L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-histidine,
and L-methionine) for transporters at NVU cell membranes
(Taslimifar et al., 2018). It has been shown that the Na+-
independent antiporter SLC7A5 (LAT1) in microvascular brain
endothelial cells (MBEC) (Smith et al., 1987; Killian and
Chikhale, 2001; Meier et al., 2002), the Na+-independent
antiporter SLC7A8 (LAT2) in astrocytes (Yudkoff et al., 1996a;
Kim et al., 2004; Braun et al., 2011), and the Na+-dependent
symporter SLC6A15 (B0AT2) in neurons (Yudkoff et al., 1996b;
Bröer et al., 2006; Bak et al., 2012) are the main regulators
of LNAAs homeostasis in the NVU (Figure 1). In vivo
monitoring of LNAA levels in individual NVU compartments
during fluctuations of plasma Phe concentrations could help
establish a better understanding of their interrelation, but there
are technological hurdles that need to be overcome to enable
corresponding experiments.
To go around these hurdles, we have employed a previously
developed computational model of NVU-LNAAs homeostasis
(Taslimifar et al., 2018) to explore in silico how plasma Phe
fluctuations influence LNAA concentrations in the NVU. In
addition, we have quantified the variations in concentration of
Phe and CL in NVU cells in relation to descriptors of plasma
Phe fluctuation, namely mean, fundamental frequency and
amplitude-to-mean ratio (Anastasoaie et al., 2008; Cleary et al.,
2013). Finally, we have employed the model to explore the impact
of therapeutic supplementation of LNAAs on the attenuation of
FIGURE 1 | Schematic representation of the neurovascular unit and the
therein expressed dominant Phe and CL transporters. The dominant Phe and
competing large neutral amino acid (CL) transporters involved in the
pathophysiology of PKU disorder include the Na+-independent antiporter
LAT1 (SLC7A5) in microvascular brain endothelial cells (MBECs), the
Na+-independent antiporter LAT2 (SLC7A8) in astrocytes and the
Na+-dependent symporter B0AT2 (SLC6A15) in neurons. The arrows specify
Phe and CL transmembrane pathways. The plasma concentration profiles of
Phe and CL are taken as the input to the neurovascular unit (NVU), based on
which concentrations in the NVU compartments are calculated.
Phe and CL concentrations in NVU cells. While this treatment
strategy has been shown to modulate the perturbed concentration
of LNAAs in brain tissue in a PKU mouse model (van Vliet et al.,
2015, 2016) and also to positively impact executive functioning
of PKU patients (Schindeler et al., 2007; van Spronsen et al.,
2010), it remains unclear how supplementation of LNAAs affects
the dynamics of Phe and CL concentration in MBECs, astrocyte
and more importantly in neurons (van Spronsen et al., 2010;
van Vliet et al., 2016).
MATERIALS AND METHODS
Transport Model
We employed a previously developed compartmental model
of NVU-LNAA homeostasis in adult rats (Taslimifar et al.,
2018), to which we refer the reader for detail. Four individual
NVU compartments are considered – MBECs, ISF, astrocytes
(ast), and neurons (neu) – within which LNAAs are assumed
to be homogeneously distributed (Figure 1). In the model,
LNAA fluxes between compartments are mediated by the
dominant transporters identified from literature, i.e., LAT1,
LAT2, and B0AT2 (Table 1). Fluxes mediated by the antiporters
LAT1 and LAT2 are a function of the following: maximum
transport rates at the BBB luminal (lum) (Vmax,LAT1,lum)
and abluminal (abl) (Vmax,LAT1,abl) membranes and astrocyte
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TABLE 1 | Model parameters.
Value Unit Reference
LAT1 (MBEC)
K
P(ISF)
m,abs,LAT1,Phe 11 µM Smith et al., 1987
Vmax,LAT1,lum,Phe 0.075 µmol/min Smith et al., 1987;
Tilgmann et al., 1992
KP(ISF)m,abs,LAT1,CL 52.9
∗ µM Smith et al., 1987
Vmax,LAT1,lum,CL 0.129∗ µmol/min Smith et al., 1987;
Tilgmann et al., 1992
RKLAT1 80 – Taslimifar et al., 2018
LAT2 (ASTROCYTE)
KISF(Ast)m,abs,LAT2,Phe 110.2
∗ µM Kim et al., 2004
Vmax,LAT2,Phe 0.1128 µmol/min Shank and Campbell,
1984; Segawa et al., 1999
KISF(Ast)m,abs,LAT2,CL 185.9
∗ µM Kim et al., 2004
Vmax,LAT2,CL 0.1494∗ µmol/min Shank and Campbell,
1984; Segawa et al., 1999
B0AT2 (NEURON)
KISF(Neu)
m,abs,B0AT2,Phe
1050 µM Bröer et al., 2006
Vmax,B0AT2,Phe 0.0086
∗ µmol/min Rao et al., 1995; Bröer
et al., 2006
KISF(Neu)
m,abs,B0AT2,CL
126.2∗ µM Bröer et al., 2006
Vmax,B0AT2,CL 0.0186
∗ µmol/min Rao et al., 1995; Bröer
et al., 2006
KISF(Neu)
m,B0AT2,Na
1050 µM Takanaga et al., 2005
19 −70 mV Smith et al., 1981
β 0.6∗ mV Takanaga et al., 2005;
Panitchob, 2015
[Na]ISF 141 mM Mori et al., 2002
[Na]Neu 40 mM Fedoroff and Vernadakis,
1986
VMBEC 3.5 µl Mori et al., 2002; Licinio
and Wong, 2009
VISF 352.6 µl Tilgmann et al., 1992;
Syková et al., 2005
VAst 742 µl Ren et al., 1992; Anderova
et al., 2011
VNeu 441.7 µl Ren et al., 1992; Setou
et al., 2004;
Hosseini-Sharifabad and
Nyengaard, 2007
∗The details of calculation processes are reported in Taslimifar et al. (2018).
membrane (Vmax,LAT2), respectively; Michaelis-Menten binding
constants in the individual NVU compartments (KP(MBEC,ISF)m,LAT1
and KISF(Ast)m,LAT2); and the LAT1 bi-directional kinetic constant
(RKLAT1), which corresponds to the ratio between the absolute
Michaelis-Menten binding constant for LAT1 in MBECs relative
to the corresponding value in the ISF and in plasma (
KMBECm,abs,LAT1
KP(ISF)m,abs,LAT1
)
(Taslimifar et al., 2018). The fluxes mediated by B0AT2
symporter are a function of Michaelis-Menten kinetic parameters
(Vmax,B0AT2 and K
ISF(Neu)
m,B0AT2); neuronal electrical potential-induced
biases for forward and backward transport rates (ε and ε′);
neuronal potential difference (1ψ), electrical bias constant (β),
Faraday constant (F), sodium charge (Z), gas constant (R), and
absolute temperature (T) [see (Taslimifar et al., 2018) for details].
To account for the approximate 1:1 stoichiometry observed for
LAT1 and LAT2 antiporters under normal physiologic conditions
(Meier et al., 2002; Verrey, 2003), at each instant we limited Phe
and CL fluxes to the lowest value between the two. The values
of kinetic parameters and compartment volumes (Vi) used in the
model are taken from literature, and are reported in Table 1. The
same values are considered for both PKU and normal physiologic
cases (Möller et al., 1997; Taslimifar et al., 2018).
Model calculations were performed as follows: We first
determined steady state (ss) concentrations of Phe and CL in
the individual NVU compartments i (
[
Phe
]i
ss and [CL]
i
ss) by
prescribing constant plasma concentrations ([Phe]Pss and [CL]Pss)
as model inputs and initializing the concentrations in the
NVU compartments based on steady state concentration values
reported in Taslimifar et al. (2018). We considered plasma Phe
concentrations from 77 µM (representing normal physiologic
condition) (Currie et al., 1995) to values above 1200 µM
(representing sever classic PKU) (Güttler et al., 1969; Regier and
Greene, 2017). Plasma CL concentration was kept constant at
739 µM (Currie et al., 1995; Bongiovanni et al., 2003).
We then prescribed fluctuating plasma Phe concentrations as
[Phe]Pf =
[
Phe
]P
ss
1+ cf [Phe]Pδ
max
∣∣∣[Phe]Pδ ∣∣∣
 , (1)
where cf is a coefficient that can take on values between 0 and 1,
and thereby scales the fluctuation amplitude (relative to mean),
and
[
Phe
]P
δ
is a periodic zero-mean fluctuating component with
zero initial value described by the trigonometric Fourier series
[
Phe
]P
δ
=
N∑
n=1
an sin
(
2pinf0t
)+ bncos (2pinf0t) , (2)
where n is an integer, fo is the fundamental frequency of Phe
fluctuation, and an and bn are the Fourier coefficients.
For presentation purposes, we initially considered three
distinct plasma Phe fluctuation profiles referred to as cases c1–
c3, with values of steady state concentration, frequency and
relative amplitude as given in Table 2. For each of these cases,
we determined the steady state concentrations of Phe and
CL (
[
Phe
]i
ss and [CL]
i
ss) as well as the fluctuating response
([Phe]if and [CL]if) in the NVU compartments. Results for
this in silico investigation are shown as time series (excluding
the initial transition from the steady state) normalized with
respect to the corresponding values for normal physiologic
conditions reported in Table 3 (determined for model input[
Phe
]P
ss = 77 µM, [CL]
P
ss = 739 µM and cf = 0; Currie et al., 1995;
Bongiovanni et al., 2003).
To further investigate the effect of fluctuations, we considered
a PKU case for which we fixed the non-fluctuating plasma
Phe and CL concentrations and varied the fluctuation indices
(fundamental frequency and amplitude-to-mean ratio) of a
purely sinusoidal signal oscillation,
[
Phe
]P
δ
= sin
(
2pif0t
)
, within
realistic bounds (0.14 ≤ f0 ≤ 7 cycles per day and 0 ≤ cf ≤ 1)
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TABLE 2 | Fluctuation indices of exemplary Phe plasma concentration profiles.
Case number [Phe]Pss (µM) f0 (cycles/day) cf (−)
c1 300 1 0.99
c2 800 3 0.3
c3 1600 0.14 0.6
TABLE 3 | Steady state normal physiologic (baseline) concentration values of Phe
and CL in the NVU.
Compartment Parameter Concentration Unit
Microvascular brain
endothelial cell
[Phe]MBECss 24.6 ± 146.8 µM
[CL]MBECss 235.7 ± 1408.8 µM
Brain interstitial fluid [Phe]ISFss 0.03 ± 0.4 µM
[CL]ISFss 0.3 ± 3.8 µM
Astrocyte [Phe]Astss 4.8 ± 40.6 µM
[CL]Astss 46.0 ± 389.7 µM
Neuron [Phe]Neuss 7.0 ± 53.4 µM
[CL]Neuss 46.9 ± 368.7 µM
The details for the calculation of the steady state conditions are reported in
Taslimifar et al. (2018). The plasma concentrations of Phe and CL are 77 and
739 µM, respectively (Currie et al., 1995; Bongiovanni et al., 2003).
(Güttler et al., 1969; MacDonald et al., 1998; Ferguson and
Morris, 1999; Michals-Matalon et al., 2007; Mitchell et al.,
2011). We, similarly, calculated the fluctuating and steady state
concentrations of Phe and CL in the NVU compartments. For
each compartment, we calculated the root mean square of the
difference between the fluctuating and steady state responses
(normalized with respect to normal physiologic conditions)
and considered it as a metric for the excursion of the
concentration of Phe and CL.
Finally, we employed the model to investigate the impact
of therapeutic supplementation of non-Phe LNAAs on the
concentrations of Phe and CL in NVU cells. To this end,
we considered the supplemented LNAAs (SL) as CL with the
same kinetics, and prescribed it as constant input (representing
the effective plasma concentration of SL) to the model. We
then determined steady state and fluctuating responses in the
NVU, considering, as model input, different values for the
effective steady state concentrations of SL in the plasma (0.5,
2, and 5 mM) and of both steady state (
[
Phe
]P
ss = 1000 and
cf = 0) and sinusoidally fluctuating plasma Phe concentration
(
[
Phe
]P
δ
= sin
(
2pif0t
)
,
[
Phe
]P
ss = 1000 µM, cf = 0.5 and f0 = 1
cycles/day). We show the responses as time series (excluding
transition from steady state) normalized with respect to the
corresponding values of baseline physiologic conditions.
Sensitivity Analysis
We evaluated the sensitivity of the reported results on the
choice of literature-reported model parameter values. To this
end, we calculated model output for 100 cases in which
the nominal model input parameters [maximum transport
rates, Michaelis–Menten binding constants and steady state
physiologic concentration values of LNAAs in individual
compartments (Tables 1, 3)] were varied randomly in a range of
±20% from their respective nominal values. In the results, the
shown upper and lower bounding curves correspond to standard
deviations of the calculated concentrations from those computed
under nominal parameter conditions.
RESULTS
NVU Steady State Condition in Relation
to Steady State Plasma Phe
Concentration
Figure 2 shows plots of steady state concentrations of Phe and
CL in neurons versus steady state concentrations of plasma Phe
from 77 µM (normal physiologic conditions) to values above
1200 µM (severe classic PKU). The reason why AA levels in
the modeled neuron reach equilibrium (even though the Na+
electrochemical force drives influx through B0AT2) is their low
extracellular concentration in the brain interstitial fluid. Phe
and CL concentrations in the other compartments are shown
in Supplementary Figure S1. In all NVU compartments, Phe
concentration increases with its plasma concentration, while
the opposite behavior is observed for CL. In Supplementary
Figure S1E, we show the steady state responses in the whole
brain tissue as volume-weighted average of the steady state
responses in the individual NVU compartments. Given that
animal species are different in terms of NVU geometry and
also kinetic characteristics of LNAA transporters (Smith et al.,
1987; Hargreaves and Pardridge, 1988; Martynyuk et al., 2010),
a 1:1 comparison between species cannot be provided for
concentration behavior of LNAA in the brain. However, the
observed growth trend we determined for Phe in whole brain
tissue in our in silico adult PKU rat brain model is qualitatively
in line with experimental observations in a PKU mouse model
(van Vliet et al., 2015; Belanger et al., 2018).
FIGURE 2 | Model calculation of the steady state concentration of Phe and
CL in neurons in relation to Phe concentration in the plasma. The bold solid
lines correspond to results obtained with nominal model parameter values.
The lower and upper bounds indicate standard deviation determined by
sensitivity analysis (see section Materials and Methods). Similar relations
between Phe and CL steady state concentrations are also observed in the
other NVU compartments (see Supplementary Figure S1).
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The Dynamics of LNAAs in the NVU Are
Influenced by Phe Concentration
Fluctuations in the Plasma
After the assessment of the NVU steady state response to steady
state plasma Phe concentrations, we calculated the dynamic
changes of Phe and CL in the NVU in response to plasma Phe
fluctuations. Figure 3 shows the evolution of the concentrations
of Phe and CL over time in MBECs (Figures 3B1–B3), brain ISF
(Figures 3C1–C3), astrocytes (Figures 3D1–D3), and neurons
(Figures 3E1–E3) for the three plasma Phe fluctuation cases
c1, c2, and c3 (Figures 3A1–A3) (normalized with respect to
normal physiologic conditions) over a span of 14 days. The
shown upper and lower bounding curves correspond to standard
deviations obtained through sensitivity analysis (see section
Materials and Methods). In all cases, the results highlight the
competition between Phe and CL: for example, the transfer of
Phe through MBEC via the antiporter LAT1 is associated with
movements of CL in reverse direction at both luminal and
abluminal BBB membranes (Figures 3B1–B3). Once Phe and
CL gain entry into the brain ISF (Figures 3C1–C3), they are
either exchanged back into MBECs through abluminal LAT1
(Figures 3B1–B3) and/or astrocytes via LAT2 (Figures 3D1–
D3), and/or co-transported along with sodium ions into neurons
via B0AT2 (Figures 3E1–E3). Additionally, in all cases, the steady
state Phe concentration in brain ISF, astrocyte and neurons are
characterized by values higher than under normal physiologic
conditions (which correspond to “baseline” or 100% in the
figure), while the opposite is observed for CL concentrations.
We also observe that the concentration dynamics of both Phe
and CL in the NVU compartments are influenced by plasma
Phe fluctuations, with the impact dependent on plasma Phe
fluctuation frequency, mean value, and amplitude-to-mean ratio.
For example, in case c1, plasma Phe fluctuations strongly affect
the dynamics of Phe and CL concentration in brain ISF and
MBECs and, to a lesser extent, in astrocytes and neurons.
FIGURE 3 | Dynamic changes in the concentrations of Phe and CL in MBECs, ISF, astrocytes and neurons in response to fluctuations of Phe concentration in the
plasma. Panel (A) shows the plasma concentration of L-phenylalanine (Phe) and competing LNAAs (CL) for the three cases c1, c2, and c3 described in the
Methods. For each case, panels (B1–B3,C1–C3,D1–D3,E1–E3) show, respectively, the computed steady state concentrations of Phe and CL concentrations
([Phe]ss and [CL]ss) as well as the fluctuating response ([Phe]f and [CL]f) in MBECs, ISF, astrocytes and neurons. The lower and upper bounds indicate standard
deviation determined by sensitivity analysis (see section Materials and Methods). The physiologic baseline concentrations of Phe and CL are reported in Table 3.
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In case c2, the variations in concentrations of Phe and CL
in astrocyte and neurons are not significant as compared to
corresponding changes in MBECs and brain ISF. Finally, in case
c3, we observe large variations in concentrations of Phe and
CL in brain ISF and MBEC, but comparably lower variations in
astrocytes and neurons.
Association Between Plasma Phe
Fluctuation and Changes in Phe and CL
Concentration in the NVU
To study how perturbations in Phe and CL concentrations in the
NVU relate to plasma Phe fluctuation indices, we simultaneously
varied f0 and cf of sinusoidally fluctuating plasma Phe
concentration, and then calculated the corresponding changes
in concentration of Phe and CL in the NVU compartments.
We thereby quantified the associations between Phe and CL
excursion and the plasma Phe frequency and amplitude-to-mean
ratio. Supplementary Figure S2 shows corresponding results
observed over a span of 14 days ([Phe]Pδ = sin
(
2pif0t
)
and
[Phe]Pss = 1600µM). The largest Phe and CL changes are observed
in all NVU compartments for large amplitude-to-mean ratio of
Phe fluctuations in the plasma. Additionally, low frequencies lead
to higher excursion for Phe and CL in astrocytes and neurons
and also in ISF for CL, whereas in the same ISF compartment the
Phe excursions are lower under low frequencies (Supplementary
Figures S2B1,2,C1,2,D1,2). Finally, we observed that in MBECs,
excursion levels are not influenced by the fluctuation frequency
and that the changes in Phe and CL concentration are also
not significantly sensitive to fluctuation frequency in the
other compartments when the fluctuation coefficient is small
(Supplementary Figures S2A1–D2).
Impact of LNAA Supplementation on Phe
and CL Concentrations in the NVU
To elucidate the impact of non-Phe LNAA supplementation,
we determined Phe and CL concentrations in neurons
(Figures 4B1,B2), MBECs (Supplementary Figures S3B1,B2),
ISF (Supplementary Figures S3C1,C2) and astrocytes
(Supplementary Figures S3D1,D2) in response to various
concentrations of SL in the plasma under both steady state
and fluctuating Phe conditions (Figures 4A1,A2). The shown
upper and lower bounding curves correspond to standard
deviations investigated by performing sensitivity analysis. Our
results show that supplementation of LNAA attenuates the
disturbed steady state concentration of Phe and CL in the
NVU and modulates their concentrations toward physiologic
baseline conditions (Table 3). This is because SL together
with CL increases the competitions between Phe and non-Phe
LNAAs through LAT1 across the BBB and thereby inhibits
FIGURE 4 | Impact of LNAA supplementation on Phe and CL concentrations in the NVU. Panels (A1,A2) show the plasma concentration of L-phenylalanine (Phe)
and competing LNAAs (CL) used as model input. Panels (B1,B2) show the model calculations for steady state concentrations of Phe and CL ([Phe]ss and [CL]ss) as
well as the fluctuating response ([Phe]f and [CL]f) in the neuronal compartment for various concentration levels of supplemented LNAAs in the plasma ([SL]
P). The
lower and upper bounds indicate standard deviation determined by sensitivity analysis (see section Materials and Methods). In all panels, the baseline physiologic
concentrations of Phe and CL are reported in Table 3.
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LAT1 mediated trans-endothelial transport of Phe fluctuations
from plasma into the brain. As a consequence, this leads to a
reduction in the amplitude level of Phe and CL fluctuations
in neurons, MBECs, ISF and astrocytes (Figures 4B1,B2 and
Supplementary Figures S3B1,B2,C1,C2,D1,D2, respectively).
In addition, the increased competition via LAT1 leads to delayed
response in neurons, ISF and astrocytes (Figures 4B1,B2 and
Supplementary Figures S3C1,C2,D1,D2, respectively).
DISCUSSION
Failure of AA homeostasis in general negatively affects cell
function (Suraweera et al., 2012). In cells of the NVU, Phe
and CL are involved in a variety of processes, including
the synthesis of essential neurotransmitters such as dopamine
(3-hydroxytyramine) and serotonin (5-hydroxytryptamine; 5-
HT) (Fernstrom, 1994, 2005; Lieberman, 2000; Cansev and
Wurtman, 2007), and the production of proteins and lipids (e.g.,
myelin) (Sperringer et al., 2017; Yudkoff, 2017), although their
function in the latter processes is not fully understood. Hence,
depending on the full set of roles of Phe and CL, oscillations
of their concentrations in the NVU could have a negative
impact on central nervous system function. However, fluctuating
NVU-LNAA concentrations are difficult to measure in animal
models of PKU. Furthermore, in patient studies, the effects of
elevated steady state plasma Phe concentration cannot be easily
differentiated from those caused by increased fluctuations in Phe.
The here introduced in silico model can serve as an alternative
tool to probe these complex dynamics quickly and quantitatively.
We first showed that with increasing Phe concentration in
plasma, the steady state concentration of Phe in the NVU and
in whole brain increases, while CL concentration decreases.
The growth trend we determined for Phe in our in silico adult
PKU rat brain model is qualitatively in line with experimental
observations in a PKU mouse model (van Vliet et al., 2015). We
then showed that the propagation of plasma Phe concentration
oscillations into the NVU largely depend on fluctuation indices
such as frequency and amplitude-to-mean ratio. We observed
the largest Phe and CL concentration excursions in the NVU for
low frequencies and large amplitude-to-mean ratios of plasma
Phe fluctuations. Additionally, we observed that, for the small
fluctuation coefficients, the sensitivity of Phe and CL excursions
to plasma Phe fluctuation frequency is not significant. Finally, we
showed that supplementation of LNAAs not only reduces steady
state concentrations in the NVU toward normal physiologic
values, but also leads to a reduction in Phe and CL fluctuation
amplitude. In conclusion, our in silico experiments support
LNAA supplementation as therapeutic strategy for reducing
the propagation of plasma Phe concentration fluctuations into
the brain. The model itself can also be seen as a potential
stepping-stone for the development of a patient-specific LNAA
supplementation treatment-planning tool.
The computational model has been built with a number
of simplifying assumptions. In particular, we focused on
the pathways mediated by dominant transporters and thus
disregarded pathways related to metabolism, diffusion and NVU
transporters with low levels of expression, which have been
shown to be of lesser importance (Sadasivudu and Lajtha, 1970;
Smith and Takasato, 1986). Additionally, we considered Phe
and CL as a homogenous mixture within the individual NVU
compartments. Furthermore, we considered CL as a single entity
rather than accounting one by one for each individual competitor,
i.e., for L-isoleucine, L-tyrosine and others. The validity of these
assumptions are discussed in more detail in Taslimifar et al.
(2018). To account for effects of uncertainties associated with the
values of the model parameters, we have performed a sensitivity
analysis demonstrating that our conclusions are robust with
respect to reasonable parameter variations.
SUMMARY
Using a computational model of adult rat NVU-LNAA
homeostasis, we investigated the effects of plasma Phe
fluctuations on the dynamics of LNAAs in MBECs, brain
ISF, astrocytes and neurons in PKU. Comparable in vivo
investigations are not readily doable with current techniques.
Our results show that plasma Phe fluctuations can propagate into
the NVU and change there the concentration of LNAAs, with
the magnitude of this effect largely dependent on the frequency
and amplitude-to-mean ratio of the plasma concentration
fluctuations. Finally, we quantified the therapeutic impact
of supplementation of LNAAs in attenuating the disturbed
fluctuating and steady state concentrations of Phe and CL in the
cells of NVU in PKU disorder toward normal physiologic levels.
AUTHOR CONTRIBUTIONS
MT implemented the computational model and performed the
calculations with SB. FV and VK directed the research. All
authors conceived and designed the study, analyzed the data,
wrote the manuscript, and approved the final version.
FUNDING
This work was financially supported by SystemsX.ch – the
Swiss Initiative in Systems Biology through the QuantX project,
and by the Swiss National Science Foundation through NCCR
Kidney.CH and grant 310030_166430.
ACKNOWLEDGMENTS
We would like to thank Nenad Blau for helpful discussions on the
fluctuation of Phe concentration in blood.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fphys.2019.
00360/full#supplementary-material
Frontiers in Physiology | www.frontiersin.org 7 April 2019 | Volume 10 | Article 360
fphys-10-00360 March 30, 2019 Time: 16:7 # 8
Taslimifar et al. Quantifying LNAA Dynamics in PKU
REFERENCES
Anastasoaie, V., Kurzius, L., Forbes, P., and Waisbren, S. (2008). Stability of blood
phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet.
Metab. 95, 17–20. doi: 10.1016/j.ymgme.2008.06.014
Anderova, M., Vorisek, I., Pivonkova, H., Benesova, J., Vargova, L., Cicanic, M.,
et al. (2011). Cell death/proliferation and alterations in glial morphology
contribute to changes in diffusivity in the rat hippocampus after hypoxia—
ischemia. J. Cereb. Blood Flow Metab. 31, 894–907. doi: 10.1038/jcbfm.
2010.168
Bak, L. K., Johansen, M. L., Schousboe, A., and Waagepetersen, H. S. (2012). Valine
but not leucine or isoleucine supports neurotransmitter glutamate synthesis
during synaptic activity in cultured cerebellar neurons. J. Neurosci. Res. 90,
1768–1775. doi: 10.1002/jnr.23072
Belanger, A. M., Przybylska, M., Gefteas, E., Furgerson, M., Geller, S., Kloss, A.,
et al. (2018). Inhibiting neutral amino acid transport for the treatment of
phenylketonuria. JCI Insight 3:121762. doi: 10.1172/jci.insight.121762
Bongiovanni, R., Yamamoto, B. K., Simpson, C., and Jaskiw, G. E. (2003).
Pharmacokinetics of systemically administered tyrosine: a comparison of
serum, brain tissue and in vivo microdialysate levels in the rat. J. Neurochem.
87, 310–317. doi: 10.1046/j.1471-4159.2003.02007.x
Braun, D., Kinne, A., Bräuer, A. U., Sapin, R., Klein, M. O., Köhrle, J., et al.
(2011). Developmental and cell type-specific expression of thyroid hormone
transporters in the mouse brain and in primary brain cells. Glia 59, 463–471.
doi: 10.1002/glia.21116
Bröer, A., Tietze, N., Kowalczuk, S., Chubb, S., Munzinger, M., Bak, L. K., et al.
(2006). The orphan transporter v7-3 (slc6a15) is a Na+-dependent neutral
amino acid transporter (B0AT2). Biochem. J. 393, 421–430. doi: 10.1042/
BJ20051273
Burgard, P., Rupp, A., Konecki, D., Trefz, F., Schmidt, H., and Lichter-
Konecki, U. (1996). Phenylalanine hydroxylase genotypes, predicted residual
enzyme activity and phenotypic parameters of diagnosis and treatment of
phenylketonuria. Eur. J. Pediatr. 155, S11–S15. doi: 10.1007/PL00014222
Cansev, M., and Wurtman, R. (2007). “4 aromatic amino acids in the brain,” in
Handbook of Neurochemistry and Molecular Neurobiology, eds A. Lajtha, S. S.
Oja, P. Saransaari, and A. Schousboe (Berlin: Springer), 59–97. doi: 10.1007/
978-0-387-30373-4_4
Cleary, M., Trefz, F., Muntau, A. C., Feillet, F., van Spronsen, F. J., Burlina, A.,
et al. (2013). Fluctuations in phenylalanine concentrations in phenylketonuria:
a review of possible relationships with outcomes. Mol. Genet. Metabol. 110,
418–423. doi: 10.1016/j.ymgme.2013.09.001
Currie, P. J., Chang, N., Luo, S., and Anderson, G. H. (1995). Microdialysis
as a tool to measure dietary and regional effects on the complete profile of
extracellular amino acids in the hypothalamus of rats. Life Sci. 57, 1911–1923.
doi: 10.1016/0024-3205(95)02178-L
Fedoroff, S., and Vernadakis, A. (1986). Astrocytes: Biochemistry, Physiology, and
Pharmacology of Astrocytes, Vol. 2. Orlando: Academic Press.
Ferguson, C., and Morris, A. (1999). Changes in serum phenylalanine after
overnight fasts in youngsters with phenylketonuria. J. Hum. Nutr. Dietet. 12,
213–218. doi: 10.1046/j.1365-277x.1999.00158.x
Fernstrom, J. D. (1994). Dietary amino acids and brain function. J. Am. Dietet.
Assoc. 94, 71–77. doi: 10.1016/0002-8223(94)92045-1
Fernstrom, J. D. (2005). Branched-chain amino acids and brain function. J. Nutr.
135, 1539S–1546S. doi: 10.1093/jn/135.6.1539S
Güttler, F., Olesen, E. S., and Wamberg, E. (1969). Diurnal variations of serum
phenylalanine in phenylketonuric children on low phenylalanine diet. Am. J.
Clin. Nutr. 22, 1568–1570. doi: 10.1093/ajcn/22.12.1568
Hargreaves, K., and Pardridge, W. (1988). Neutral amino acid transport at the
human blood-brain barrier. J. Biol. Chem. 263, 19392–19397.
Hood, A., Antenor-Dorsey, J. A. V., Rutlin, J., Hershey, T., Shimony, J. S.,
McKinstry, R. C., et al. (2015). Prolonged exposure to high and variable
phenylalanine levels over the lifetime predicts brain white matter integrity in
children with phenylketonuria. Mol. Genet. Metab. 114, 19–24. doi: 10.1016/j.
ymgme.2014.11.007
Hood, A., Grange, D. K., Christ, S. E., Steiner, R., and White, D. A. (2014).
Variability in phenylalanine control predicts IQ and executive abilities in
children with phenylketonuria. Mol. Genet. Metabol. 111, 445–451. doi: 10.
1016/j.ymgme.2014.01.012
Hosseini-Sharifabad, M., and Nyengaard, J. R. (2007). Design-based estimation
of neuronal number and individual neuronal volume in the rat hippocampus.
J. Neurosci. Methods 162, 206–214. doi: 10.1016/j.jneumeth.2007.
01.009
Killian, D. M., and Chikhale, P. J. (2001). Predominant functional activity of the
large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature.
Neurosci. Lett. 306, 1–4. doi: 10.1016/S0304-3940(01)01810-9
Kim, D. K., Kim, I. J., Hwang, S., Kook, J. H., Lee, M. C., Shin, B. A., et al. (2004).
System L-amino acid transporters are differently expressed in rat astrocyte and
C6 glioma cells. Neurosci. Res. 50, 437–446. doi: 10.1016/j.neures.2004.08.003
Licinio, J., and Wong, M.-L. (2009). Pharmacogenomics: The Search for
Individualized Therapies. Hoboken: John Wiley & Sons.
Lieberman, H. R. (2000). Amino Acid and Protein Requirements: Cognitive
Performance, Stress, and Brain Function. Natick MA: Army Research Inst Of
Environmental Medicine.
MacDonald, A., Rylance, G., Asplin, D., Hall, S., and Booth, I. (1998). Does a single
plasma phenylalanine predict quality of control in phenylketonuria? Arch. Dis.
Child. 78, 122–126. doi: 10.1136/adc.78.2.122
Madden, M. (2004). Phenylketonuria: defects in amino acid metabolism. Mol. Med.
5, 57–61.
Martynyuk, A., Van Spronsen, F., and Van der Zee, E. (2010). Animal models
of brain dysfunction in phenylketonuria. Mol. Genet. Metab. 99, S100–S105.
doi: 10.1016/j.ymgme.2009.10.181
Meier, C., Ristic, Z., Klauser, S., and Verrey, F. (2002). Activation of system L
heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 21,
580–589. doi: 10.1093/emboj/21.4.580
Michals-Matalon, K., Bhatia, G., Guttler, F., Tyring, S. K., and Matalon, R. (2007).
Response of phenylketonuria to tetrahydrobiopterin. J. Nutr. 137, 1564S–1567S.
doi: 10.1093/jn/137.6.1564S
Mitchell, J. J., Trakadis, Y. J., and Scriver, C. R. (2011). Phenylalanine hydroxylase
deficiency. Genet. Med. 13:697. doi: 10.1097/GIM.0b013e3182141b48
Möller, H. E., Weglage, J., Wiedermann, D., Vermathen, P., Bick, U., and Ullrich, K.
(1997). Kinetics of phenylalanine transport at the human blood–brain barrier
investigated in vivo. Brain Res. 778, 329–337. doi: 10.1016/S0006-8993(97)
01054-8
Mori, K., Miyazaki, M., Iwase, H., and Maeda, M. (2002). Temporal profile
of changes in brain tissue extracellular space and extracellular ion (Na+,
K+) concentrations after cerebral ischemia and the effects of mild cerebral
hypothermia. J. Neurotrauma 19, 1261–1270. doi: 10.1089/089771502603
38047
Panitchob, N. (2015). Computational Modelling of Amino Acid Transfer
Interactions in the Placenta. Doctoral thesis, University of Southampton,
Southampton.
Rao, K. R., Vemuri, M. C., and Murthy, C. R. (1995). Synaptosomal
transport of branched chain amino acids in young, adult and aged rat
brain cortex. Neurosci. Lett. 184, 137–140. doi: 10.1016/0304-3940(94)
11189-P
Regier, D. S., and Greene, C. L. (2017). “Phenylalanine hydroxylase deficiency,”
in GeneReviews R© [Internet], eds M. P. Adam, H. H. Ardinger, R. A. Pagon,
et al. (Seattle: University of Washington). Available at: https://www.ncbi.nlm.
nih.gov/books/NBK1504/
Ren, J., Aika, Y., Heizmann, C., and Kosaka, T. (1992). Quantitative analysis of
neurons and glial cells in the rat somatosensory cortex, with special reference to
GABAergic neurons and parvalbumin-containing neurons. Exp. Brain Res. 92,
1–14. doi: 10.1007/BF00230378
Romani, C., Palermo, L., MacDonald, A., Limback, E., Hall, S. K., and
Geberhiwot, T. (2017). The impact of phenylalanine levels on cognitive
outcomes in adults with phenylketonuria: effects across tasks and
developmental stages. Neuropsychology 31:242. doi: 10.1037/neu0000336
Sadasivudu, B., and Lajtha, A. (1970). Metabolism of amino acids in incubated
slices of mouse brain. J. Neurochem. 17, 1299–1311. doi: 10.1111/j.1471-4159.
1970.tb03379.x
Schindeler, S., Ghosh-Jerath, S., Thompson, S., Rocca, A., Joy, P., Kemp, A., et al.
(2007). The effects of large neutral amino acid supplements in PKU: an MRS
and neuropsychological study. Mol. Genet. Metabol. 91, 48–54. doi: 10.1016/j.
ymgme.2007.02.002
Segawa, H., Fukasawa, Y., Miyamoto, K., Takeda, E., Endou, H., and Kanai, Y.
(1999). Identification and functional characterization of a Na+-independent
Frontiers in Physiology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 360
fphys-10-00360 March 30, 2019 Time: 16:7 # 9
Taslimifar et al. Quantifying LNAA Dynamics in PKU
neutral amino acid transporter with broad substrate selectivity. J. Biol. Chem.
274, 19745–19751. doi: 10.1074/jbc.274.28.19745
Setou, M., Hayasaka, T., and Yao, I. (2004). Axonal transport versus dendritic
transport. J. Neurobiol. 58, 201–206. doi: 10.1002/neu.10324
Shank, R. P., and Campbell, G. L. (1984). Amino acid uptake, content, and
metabolism by neuronal and glial enriched cellular fractions from mouse
cerebellum. J. Neurosci. 4, 58–69. doi: 10.1523/JNEUROSCI.04-01-00058.1984
Smith, Q. R., Johanson, C. E., and Woodbury, D. M. (1981). Uptake of 36Cl and
22Na by the brain-cerebrospinal fluid system: comparison of the permeability
of the blood-brain and blood-cerebrospinal fluid barriers. J. Neurochem. 37,
117–124. doi: 10.1111/j.1471-4159.1981.tb05298.x
Smith, Q. R., Momma, S., Aoyagi, M., and Rapoport, S. I. (1987). Kinetics of
neutral amino acid transport across the blood-brain barrier. J. Neurochem. 49,
1651–1658. doi: 10.1111/j.1471-4159.1987.tb01039.x
Smith, Q. R., and Takasato, Y. (1986). Kinetics of amino acid transport at the blood-
brain barrier studied using an in situ brain perfusion technique. Ann. N. Y.
Acad. Sci. 481, 186–201. doi: 10.1111/j.1749-6632.1986.tb27150.x
Sperringer, J. E., Addington, A., and Hutson, S. M. (2017). Branched-chain amino
acids and brain metabolism. Neurochem. Res. 42, 1697–1709. doi: 10.1007/
s11064-017-2261-5
Suraweera, A., Münch, C., Hanssum, A., and Bertolotti, A. (2012). Failure of amino
acid homeostasis causes cell death following proteasome inhibition. Mol. Cell
48, 242–253. doi: 10.1016/j.molcel.2012.08.003
Syková, E., Voøíšek, I., Antonova, T., Mazel, T., Meyer-Luehmann, M., Jucker, M.,
et al. (2005). Changes in extracellular space size and geometry in APP23
transgenic mice: a model of alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A.
102, 479–484. doi: 10.1073/pnas.0408235102
Takanaga, H., Mackenzie, B., Peng, J.-B., and Hediger, M. A. (2005).
Characterization of a branched-chain amino-acid transporter SBAT1
(SLC6A15) that is expressed in human brain. Biochem. Biophys. Res. Commun.
337, 892–900. doi: 10.1016/j.bbrc.2005.09.128
Taslimifar, M., Buoso, S., Verrey, F., and Kurtcuoglu, V. (2018). Functional
polarity of microvascular brain endothelial cells supported by neurovascular
unit computational model of large neutral amino acid homeostasis. Front.
Physiol. 9:171. doi: 10.3389/fphys.2018.00171
Tilgmann, C., Melen, K., Lundström, K., Jalanko, A., Julkunen, I., Kalkkinen, N.,
et al. (1992). Expression of recombinant soluble and membrane-bound catechol
O-methyltransferase in eukaryotic cells and identification of the respective
enzymes in rat brain. Eur. J. Biochem. 207, 813–821. doi: 10.1111/j.1432-1033.
1992.tb17112.x
van Spronsen, F. J., de Groot, M. J., Hoeksma, M., Reijngoud, D.-J., and van
Rijn, M. (2010). Large neutral amino acids in the treatment of PKU: from
theory to practice. J. Inher. Metab. Dis. 33, 671–676. doi: 10.1007/s10545-010-
9216-1
van Vliet, D., Bruinenberg, V. M., Mazzola, P. N., van Faassen, M. H., de
Blaauw, P., Kema, I. P., et al. (2015). Large neutral amino acid supplementation
exerts its effect through three synergistic mechanisms: proof of principle
in phenylketonuria mice. PLoS One 10:e0143833. doi: 10.1371/journal.pone.
0143833
van Vliet, D., Bruinenberg, V. M., Mazzola, P. N., van Faassen, M. H., de Blaauw, P.,
Pascucci, T., et al. (2016). Therapeutic brain modulation with targeted large
neutral amino acid supplements in the Pah-enu2 phenylketonuria mouse
model. Am. J. Clin. Nutr. 104, 1292–1300. doi: 10.3945/ajcn.116.135996
Verrey, F. (2003). System L: heteromeric exchangers of large, neutral amino acids
involved in directional transport. Pflügers Archiv. 445, 529–533. doi: 10.1007/
s00424-002-0973-z
Viau, K. S., Wengreen, H. J., Ernst, S. L., Cantor, N. L., Furtado, L. V.,
and Longo, N. (2011). Correlation of age-specific phenylalanine levels with
intellectual outcome in patients with phenylketonuria. J. Inher. Metab. Dis. 34,
963–971. doi: 10.1007/s10545-011-9329-1
Yudkoff, M. (2017). Interactions in the metabolism of glutamate and the branched-
chain amino acids and ketoacids in the CNS. Neurochem. Res. 42, 10–18. doi:
10.1007/s11064-016-2057-z
Yudkoff, M., Daikhin, Y., Grunstein, L., Nissim, I., Stern, J., Pleasure, D., et al.
(1996a). Astrocyte leucine metabolism: significance of branched-chain amino
acid transamination. J. Neurochem. 66, 378–385.
Yudkoff, M., Daikhin, Y., Nelson, D., Nissim, I., and Erecin´ska, M. (1996b).
Neuronal metabolism of branched-chain amino acids: flux through the
aminotransferase pathway in synaptosomes. J. Neurochem. 66, 2136–2145.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Taslimifar, Buoso, Verrey and Kurtcuoglu. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 360
